anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vaccine comprising a virus having the designation ATCC VR2509 is claimed. Also claimed are: (1) an isolated and purified North American porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) strain where the strain has the designation ATCC VR2509, and (2) an isolated and purified PRRSV strain, wherein the strain gives plaques having an average dia. of  2 mm when the plaques are obtd. by a method comprising: (a) inoculating an aliquot of cells with the strain, where the cells have the designation ATCC VR2509, where the aliquot is obtd. from a confluent monolayer of the cells maintained in Eagle's min. essential medium (MEM) supplemented with 3% fetal calf serum and 0.15% sodium carbonate, where the aliquot includes 1-2\*105 cells/ml of MEM, (b) incubating the aliquot at 37  deg C for 60 mins, (c) removing the inoculum from the aliquot, (d) washing the aliquot with MEM, (e) resuspending the aliquot in 5 ml of 2X MEM and 1.6% boiled Noble agar supplemented with 250 ~mg of diethylaminoethyl (DEAE)- dextran, (f) plating the aliquot and (g) further incubating the aliquot at 37  deg C for 5 days in CO2 incubator to give the plaques.
The invention concerns a method and device for automatic classification of the difference between normal and abnormal lung images, abnormal lung images being attributed to disease. Certain physical structural measurements are analysed, and a database for normal lungs is searched to determine whether these structural measurements are contained in it. The selected structural measurements are the oscillation in the root mean square R, and the first moment of the power spectrum M, for a lung structure. These two structural measurements are normalised using the database for normal lungs. A single structure index is determined from the two normalised structural measurements, by taking into account the distribution (or database) of the structural measurements obtained from abnormal lungs, to simplify the automatic classification of normal and abnormal lungs. Interesting areas are defined, and selected abnormal interesting areas are submitted to three different tests.
CD19 chimeric antigen receptor (CAR) T-cell therapy has proven highly effective for treating relapsed/refractory mantle cell lymphoma (MCL). However, immune effector cell-associated neurotoxicity syndrome (ICANS) remains a significant concern. This study aimed to evaluate the clinical, radiological, and laboratory correlatives associated with ICANS development after CD19 CAR T-cell therapy in patients with MCL. All patients (N = 26) who received standard-of-care brexucabtagene autoleucel until July 2022 at our institution were evaluated. Laboratory and radiographic correlatives including brain magnetic resonance imaging (MRI) and electroencephalogram (EEG) were evaluated to determine the clinical impact of ICANS. Seventeen (65%) patients experienced ICANS after treatment, with a median onset on day 6. Ten (38%) patients experienced severe (grade ≥3) ICANS. All patients with ICANS had antecedent cytokine release syndrome (CRS), but no correlation was observed between ICANS severity and CRS grade. Overall, 92% of EEGs revealed interictal changes; no patients experienced frank seizures because of ICANS. In total, 86% of patients with severe ICANS with postinfusion brain MRIs demonstrated acute neuroimaging findings not seen on pretreatment MRI. Severe ICANS was also associated with higher rates of cytopenia, coagulopathy, increased cumulative steroid exposure, and prolonged hospitalization. However, severe ICANS did not affect treatment outcomes of patients with MCL. Severe ICANS is frequently associated with a range of postinfusion brain MRI changes and abnormal EEG findings. Longer hospitalization was observed in patients with severe ICANS, especially those with abnormal acute MRI or EEG findings, but there was no discernible impact on overall treatment response and survival.
This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.
FIELD: medicine. SUBSTANCE: method involves treating catamanestic treatment period using scheme corresponding to the primary hospital treatment with some measures aimed at muscular hypertonia and arterial hypertension reduction, being intensified. Arterial hypertension is treated with pharmacological preparations in combination with psychotherapy. Muscular hypertonia reduction is achieved by administering myorelaxants in combination with antiparkinsonian means at a doses permitted to treatment. Madopar, Midanton, Cyclodol, are applied as the antiparkinsonian drugs and Baclaphen, Syndralud, Myolastin are applied as the myorelaxants. EFFECT: enhanced effectiveness of rehabilitation measures. 2 cl, 3 tbl
Human anatomy education serves as a gateway for entering the intricacies of health science. Human cadavers have been the gold standard for learning regional and gross anatomy. However, increasing barriers in acquisition, maintenance, and longevity have pushed anatomy education toward technology-based alternatives such as the Anatomage Table (AT), an interactive, life-sized virtual dissection table with many anatomy education-centric features. The AT has found purchase in various contexts, such as clinical settings, research, outreach, and education. Studies into the efficacy of the AT in teaching settings have been generally positive but limited in its application, particularly in clinical procedure education. In this study, we conducted an informal workshop for second-year Certified Registered Nurse Anesthetist (CRNA) students to aid in being able to identify the important neuraxial landmarks for performing peripheral nerve blocks (PNBs), an anesthetic technique often used before other procedures. In our workshop, we paired the AT with identification of the same neuraxial landmarks on volunteer models with an ultrasound probe to provide students with relevant tactile experience for the procedure. From our pre-/post-surveys of the participants (n = 29), we found that our workshop significantly increased student confidence in identifying the relevant neuraxial landmarks for and in performing PNBs. Our results support the use of the AT in clinical education as a supplement, particularly where other anatomic teaching tools, such as cadaver models, may be too difficult to implement.NEW & NOTEWORTHY We implemented the Anatomage Table (AT) and portable ultrasound to teach neuraxial landmarks for performing peripheral nerve blocks (PNB), an anesthetic technique for Certified Registered Nurse Anesthetist (CRNA) students. The workshop significantly increased student confidence in identifying the relevant neuraxial landmarks for performing PNBs. Our results support the use of the AT in clinical education as a supplement.
Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 every 21 days or days 1, 8, and 15 every 28 days. Patients may also receive bevacizumab IV over 90 minutes on day 1 every 21 days or days 1 and 15 every 28 days. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
This study aimed to compare the effectiveness of platelet-rich fibrin clot (PRF) and conventional oroantral communication (OAC) repair techniques following tooth extractions from the maxilla. The study involved 22 patients, divided into 2 groups: a study group treated with PRF and a control group undergoing conventional OAC repair. The primary outcome measured was the effectiveness of OAC closure, with pain intensity and postoperative complications as secondary outcomes. Cone-beam computed tomography (CBCT) was used to evaluate post-extraction bone regeneration. Pain was assessed using the Visual Analogue Scale (VAS) on days 0, 1, 7, and 14 postoperatively. The results showed that the PRF group experienced a significant decrease in pain within the first 24 hours and after 7 days (P < .0001; P < .05). In contrast, complications were reported in 45.45% of patients in the conventional repair group and 18.18% in the A-PRF group. Three months postsurgery, CBCT revealed appreciable bone healing in both groups, with no significant difference (P > .05). In conclusion, the study suggests that A-PRF treatment for OACs resulted in fewer complications and quicker pain reduction than traditional repair methods, making it a promising alternative for managing OACs. However, future studies are needed to confirm these findings and establish the full therapeutic potential of PRF.
Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m\^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m\^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10\^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the first half of the study. Traditional workstation within the second half of the study.
A lifestyle preferences management system is provided. The system may collect and organize data regarding various foods and/or beverages that one or more local restaurants may offer and recommend a particular restaurant and/or menu item to a particular user based on the known dietary preferences and geographical location of the user. The system also may generate custom menu items for each user based on a cross-section of the user's known dietary preferences and the availability of substitutions, additions and/or deletions for a given menu item resulting in a dish that conforms to the user's preferences. The system also may facilitate the ordering of food from one or more vendors for a group of users while considering the dietary and/or lifestyle preferences of each member of the group in aggregate. The system also may utilize machine learning to learn a user's eating habits (e.g., by type of food, time of day, day of the week, geographical location, weather conditions, etc.) and offer recommendations for food services from vendors that anticipate the user's desires and/or preferences. The system also may provide payment systems, delivery systems, inventory management, and other functionalities.
This study aims to investigate a two-phase rebreather system (Revoxa Oxygen Rebreather device) among hospitalized patients requiring oxygen therapy. This system can deliver a high fraction of inspired oxygen (FiO2) using a very low flow oxygen source with reduced or no aerosolization. This could provide effective respiratory support with reduced waste and risk of spreading of infectious particles. Such a device could also be used in field hospitals and other makeshift care centers in the event of a surge in demand, because it obviates the need for the type of high-flow oxygen infrastructure that is typically limited to hospital settings.

This is a prospective comparative study of sequential interventions to evaluate the ability of the Revoxa Oxygen Rebreather device (RO) to improve and maintain oxygen saturation at satisfactory levels compared to conventional low-flow supplemental oxygen delivery (COD) via nasal cannula or face mask. Prior to conducting study procedures in the patient population, feasibility of trial procedures will be determined among 3 healthy adults (Group A). The initial procedural test in a healthy sample will not be included in the endpoint assessment. Following initial trial conduct in a healthy sample, 20 adult patients requiring supplemental oxygen will be recruited: adults with non-severe hypoxemia (Group B), followed by enrollment of adults with hypoxemia of any severity not requiring mechanical ventilation (Group C). Baseline measures of oxygen saturation, oxygen flow rate, vital signs (respiratory rate, heart rate, and blood pressure), and patient self-reported dyspnea and comfort will be recorded prior to initiating treatment. Following baseline measurement, either conventional low-flow oxygen delivery or oxygen via the Revoxa Oxygen Rebreather device will be initiated for 20 minutes, followed by the other modality for 20 minutes. To avoid any bias that may be introduced by a fixed sequence of device utilization (eg. COD, then RO), the order in which devices are used will be determined quasi-randomly based on whether the patient is enrolled on an odd numbered day, or an even numbered day. Vital signs, supplemental oxygen, and self-reported dyspnea measures are captured during both treatment regimens. Participants may verbally withdraw at any time by contacting one of the clinical or research staff. At that point, all data collection relating to the withdrawn study participant will be terminated. If the participant wishes, all existing data will be deleted (with the exception of the signed consent form and data related to the consent withdrawal - including the reason for the withdrawal). Additional participants will be recruited to maintain an adequate sample size in the event that participants are withdrawn from the study.
PURPOSE: To easily and conveniently produce a high-purity polyoxyalkylenemonoamine contg. no unreacted material nor by-product by subjecting a specific polyoxyalkylene compd. to cyanoethylation, hydrogenation, and purification. CONSTITUTION: A polyoxyalkylenemonoamine represented by formula II [wherein R<1> is a 1-24C hydrocarbon group or acyl; AO is 3-4C oxyalkylene; m is 1-1,000 and n is 0-1,000 provided m+n is 1-1,000 and n/(m+n) is 0.5 or lower; and when n is 1 or higher, oxyethylene units and AO are added in block or randomly] is obtd. by subjecting a polyoxyalkylene compd. of formula I (wherein R<1> , AO, m, and n are each the same as in formula II) to cyanoethylation in the presence of 0.0012wt.% (based on the reaction system) aq. soln. contg. 1-50wt.% at least one alkali catalyst selected from among potassium hydroxide, sodium hydroxide, and lithium hydroxide, then to hydrogenation with Raney nickel, and to purification with an ion-exchange resin.
NEED FOR THE STUDY Autogenous soft tissue grafts are widely used to increase the width of keratinized tissue.1 The free gingival graft (FGG) procedure is a harvesting technique that creates an open wound that heals by secondary intention. Retarded wound healing, excessive bleeding, and postoperative pain have been reported after FGG procedures. To overcome these problems, several techniques and products have been developed. Hemostatic agents such as ferric sub-sulfate solution, absorbable synthetic collagen, absorbable gelatin sponge, or oxidized regenerated cellulose. The agents are often combined with a surgical stent designed to cover the donor site, providing protection and pressure hemostasis. However, these materials may cause adverse effects such as allergies or foreign body reactions or retarded healing of the wound. An optimal method to reduce patient morbidity and enhance early wound healing in the palatal donor site has not yet been defined. Therefore, obtaining new materials that provide better wound care by decreasing bacterial contamination and enhancing wound healing has been considered an essential demand.

Recently, Lasers are also considered a good choice for wound coverage of the donor site due to effective tissue ablation, and hemostatic and bactericidal effects. Laser exhibits hemostatic effects due to its 'hot-tip' effect caused by heat accumulation at the end of the fibre. This produces a thick coagulation layer called a laser bandage or biological bandage. It is also referred to as the 'char layer' or 'eschar on the treated surface. Coleton placed a biological bandage in the donor site using C02 Laser, set at 5W continuous wave in ablative mode. Low and Convissar used erbium laser settings of low wattage with no water, some air and few pulses per second to create laser bandage to achieve coagulation. Since Diode laser also exhibits excellent thermal effects with deep tissue penetrative properties, it enhances coagulation. the investigator proposes Laser Bandage (LB) could also enhance wound healing and reduces subjective postoperative complications in the palatal donor area after harvesting FGG in a similar way.

To date, no studies have evaluated and compared if the diode laser bandage method is more effective than other palatal wound protection methods. Hence, the current study which is first of a kind is undertaken with the objectives of evaluating the effectiveness of Diode LB in achieving donor site hemostasis and comparing wound healing with a standardized palatal haemostatic agent in gel form with the surgical stent in a randomized controlled fashion.
BACKGROUND: Platelets prevent bleeding in a variety of inflammatory settings, the adhesion receptors and activation pathways involved being highly context-dependent and functionally redundant. In some situations, platelets recruited to inflammatory sites act independently of aggregation. The mechanisms underlying stable platelet adhesion in inflamed microvessels remain incompletely understood, in particular, whether and if so, how β1 and β3 integrins are involved.
METHODS: The impact of isolated or combined platelet deficiency in β1 and β3 integrins on inflammation-associated hemostasis was investigated in 3 models of acute inflammation: immune complex-based cutaneous reverse passive Arthus reaction, intranasal lipopolysaccharide-induced lung inflammation, and cerebral ischemia-reperfusion following transient (2-hour) occlusion of the middle cerebral artery.
RESULTS: Mice with platelet-directed inactivation of Itgb1 (PF4Cre-β1-/-) displayed no bleeding in any of the inflammation models, while mice defective in platelet Itgb3 (PF4Cre-β3-/-) exhibited bleeding in all 3 models. Remarkably, the bleeding phenotype of PF4Cre-β3-/- mice was exacerbated in the reverse passive Arthus model by the concomitant deletion of β1 integrins, PF4Cre-β1-/-/β3-/- animals presenting increased bleeding. Intravital microscopy in reverse passive Arthus experiments highlighted a major defect in the adhesion of PF4Cre-β1-/-/β3-/- platelets to inflamed microvessels. Unlike PF4Cre-β1-/- and PF4Cre-β3-/- mice, PF4Cre-β1-/-/β3-/- animals developed early hemorrhagic transformation 6 hours after transient middle cerebral artery occlusion. PF4Cre-β1-/-/β3-/- mice displayed no more bleeding in lipopolysaccharide-induced lung inflammation than PF4Cre-β3-/- animals.
CONCLUSIONS: Altogether, these results show that the requirement for and degree of functional redundancy between platelet β1 and β3 integrins in inflammation-associated hemostasis vary with the inflammatory situation.
Children in group A (control group N=15, Female =8, Male=7)received specially designed physical therapy program.Facilitation of balance reactions from standing position including; standing on balance board, standing on one leg, weights shifting from standing position and stoops and recover from standing,Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands,Gait training activities including: walking on balance board, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs,Facilitation of protective reaction from standing position by pushing the child in different directions.Facilitation of rising mechanism through changing position e.g.: from lying to standing and from sitting to standing,Strengthening exercises for back and abdominal muscles as well as upper and lower limbs,Jumping in place and jumping a board.
The invention discloses a functional bifidobacterium microcapsule preparation. The edible gel composed of sodium alginate and gelatin is used as capsule wall material, and the sodium alginate, the gelatin and CaCO are mixed in a certain proportion 3 Mixing with Bacillus bifidus bacterial liquid, and spraying CaCl to certain concentration 2 Prepared in solution. The capsule wall material is safe and nontoxic, can not be decomposed by Bacillus bifidus, and is cheap and easily available. The preparation process is simple, the preparation is convenient, the practicability is strong, the microencapsulation rate and the survival rate of thalli are high, the diameter of the prepared microcapsule is 1-2 mm, and the content of viable bacteria reaches 10 9 cfu/g or more. It has good gastric acidity resistance, bile salt resistance and enteric solubility, and realizes the probiotic effect of the bifidobacterium on human bodies. The Bifidobacterium microcapsule has reduced sensitivity to temperature and oxygen in yogurt matrix, enhanced acid resistance, improved storage stability, and prolonged storage life of viable bacteria. Solves the technical problems of short living bacteria preservation period and low living bacteria number of the bifidobacterium dairy products in the development process.
Kyushu Shinkansen and conventional railway lines run parallel in the areas 5 km north of Kumamoto Station (northern area) and 12 km south of the station (southern area). Following the operation of the Kyushu Shinkansen Line in 2011, the adjacent conventional railway line in the north was elevated, a new station was operated in the south, and large earthquakes struck the Kumamoto area from March to April 2016. Sleep disturbances were compared before and after the interventions and earthquakes based on noise source (Shinkansen and conventional railways), area (northern and southern), and house type (detached and apartment) through socio-acoustic surveys from 2011 to 2017. The Shinkansen railway caused significantly less sleep disturbances in detached houses in the north after compared to before the earthquakes, presumably due to more frequent closures of bedroom windows in northern detached houses following the earthquakes. The Shinkansen railway caused significantly more sleep disturbances in apartments in the south after compared to before the earthquakes, presumably because the Shinkansen slowed down immediately after the earthquakes and returned to normal speed during the survey, suddenly increasing the noise exposure. There was no significant difference in the other six cases investigated. Overall, the interventions may not have caused significant differences in sleep disturbances. This article expands on the congress paper by Morihara et al. presented in the "Community Response to Noise" session at the 52nd International Congress and Exhibition on Noise Control Engineering in Makuhari, Japan, organized by the International Institute of Noise Control Engineering.
Participants will be maintained on a stable dose of SGA and receive 12-16 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.